Helsinn and Mundipharma China Pharmaceutical are collectively announcing the approval by NMPA of Akynzeo(R) oral formulation in China

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the leading pain management market, today jointly announced that Akynzeo ® has been approved by the National Medical Products Administration (NMPA) for the therapy…

Exclusive distribution agreement signed by Helsinn

Helsinn, a Swiss pharmaceutical gathering concentrated on structure quality malignant growth care items, together with Blanver Farmoquímica e Farmacêutica S.A., a Brazilian organization concentrated on imaginative items with astounding medications and dynamic pharmaceutical fixings, resolved to extend patient access, and…

Helsinn & Endo Publicize their Agreement for the Paladin Labs Incorporation

Endo International plc (NASDAQ: ENDP) and Helsinn, a Swiss pharmaceutical gathering concentrated on structure quality disease care items, are satisfied to declare today that Endo International plc’s auxiliary Endo Ventures Limited has gone into authoritative concurrences with Helsinn to enroll,…

Helsinn

Appointment of COO, GGM and Giorgio Calderari to the Helsinn’s Board of Directors

The Switzerland-based pharma firm which focuses on the development of standard cancer care products, Helsinn, made an announcement today that Chief Operating Officer of the firm, Group General Manager, as well as, Giorgio Calderari have been appointed to the Board…

Helsinn and Mundipharma China Pharmaceutical collectively announces the launching of the ALOXI IV in China along with a Co-Detailing teamwork in Shanghai

Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai Lugano, Switzerland, and Beijing, China, May 9, 2019: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, and…